According to a recent analysis published in Surgical Endoscopy, the cost of weekly injections of popular anti-obesity medications, such as liraglutide (Saxenda) and semaglutide (Wegovy), surpasses that of metabolic and bariatric surgery within less than a year. Researchers from USF Health Morsani College of Medicine in Tampa, FL, compared the cumulative costs of pharmacotherapy with GLP-1 agonists to the one-time expenses of surgical procedures, specifically sleeve gastrectomy and Roux-en-Y gastric bypass. This analysis provides vital insights into the financial considerations associated with treating obesity through surgical and pharmaceutical methods.
Key Findings
The researchers noted that bariatric surgery offers a more permanent and rapid resolution to obesity and metabolic syndrome, presenting significant long-term cost-saving benefits. They emphasized that bariatric surgery consistently leads to:
- A substantial reduction in the use and cost of medications post-surgery.
- Decreased clinic and emergency room visits.
- A reduction in all-cause mortality, contributing to significant overall savings.
Expert Insights
Dr. Ann M. Rogers, President of the American Society for Metabolic and Bariatric Surgery (ASMBS), highlighted that studies consistently demonstrate the efficacy of metabolic surgery in achieving long-term diabetes remission and substantial weight loss. She pointed out that these outcomes far surpass those achieved through medical management or lifestyle changes alone. This not only improves health but also leads to considerable cost savings, reinforcing the need for patients to consider surgical options and for insurers to broaden access to this gold standard treatment for obesity.
Context and Statistics
The ASMBS reported that nearly 280,000 metabolic and bariatric procedures were performed in the U.S. in 2022. This figure represents only about 1% of those eligible based on BMI criteria. According to the U.S. Centers for Disease Control and Prevention (CDC), the obesity rate in the U.S. is approximately 40%, with severe obesity affecting about 1 in 10 individuals.
About Metabolic and Bariatric Surgery
Metabolic and bariatric surgery, including gastric bypass and sleeve gastrectomy, has proven to be the most effective and lasting treatment for severe obesity. These procedures not only improve or resolve conditions such as type 2 diabetes, heart disease, and high blood pressure, but they also result in significant and durable weight loss. Importantly, the safety profile of these surgeries is comparable to other commonly performed procedures in the U.S., including gallbladder surgery, appendectomy, and knee replacement.
Related Topic:
What Private Health Insurance Covers Weight Loss Surgery
